While many are hopeful that 2021 will bring better times than 2020, there’s much we don’t know about what this new year has in store. One thing we do know, points out the author of today’s article, is that “there will be new problems needing more tech, and tech investors are ever-ready to pounce when that time comes.” As such,…
The thing that created the conditions that made 2020 so awful for so many – the coronavirus pandemic – also created the conditions for tech to stage an impressive rally. The three promising tech stocks highlighted in today’s article, however, did not participate in that rally. As a result, these underperforming stocks “still trade at levels that leave room for…
While the most important decisions made by the FDA in December were undoubtedly the Emergency Use Authorizations for two COVID-19 vaccines, the month also saw a number of firsts on the regulatory front, including the authorization of the first test allowing for at-home collection of patient samples to detect both COVID-19 and influenza A and B. Now, today’s article takes…
Noting how difficult it can be for investors to understand what’s happening in the biotech industry generally and at specific biotech companies, the author of today’s article explains that he tends to invest “in companies that have a track record of working with existing products while successfully developing pipelines of new products” and in “picks-and-shovels companies that get paid to…
While the pharma/biotech sector was not spared COVID-19 pain this year, with various companies hit hard by disruptions in clinical studies and delays in elective surgeries and in individuals seeking medical care, the authors of today’s article note that “some biotech stocks have more than doubled during this period, especially those focusing on developing a coronavirus vaccine.” They proceed to…
Compelling clinical trial data and decisions from the FDA could send one, two, or all three of the biotech stocks highlighted in today’s article through the roof next year. For a look at each of these three biotech stocks and their respective catalysts – as well as a consideration of the potential pitfalls associated with each of them – CLICK…
Today’s article highlights “a low-risk, high-quality small biotech with high growth potential.” More specifically, this “is a revolutionary biotech company that uses tissue engineering to treat/repair sports-related injuries and severe burns” – and while it was negatively impacted this year by the canceling and delaying of elective surgeries due to COVID-19, the author outlines why rapid growth should return in…
Biotech bulls see a bright year ahead for the sector thanks to a range of catalysts outside of COVID. As today’s article explains, “Among the most closely tracked catalysts are the potential approval of Biogen Inc.’s experimental drug for Alzheimer’s disease, expectations for a rebound in deal-making activity, and innovations from gene therapy updates to next-generation cancer technologies.” For more…
“In light of all the focus on a coronavirus vaccine, most people tend to overlook the other happenings in the industry,” notes the author of today’s article. He reminds us that, even in the midst of a global pandemic, research has continued on treatments and drugs for cancers, genetic diseases, rare diseases and more – and he highlights three biotech…
With COVID-19 vaccine stocks Pfizer and Moderna receiving so much attention, the author of today’s article notes that “This leaves a lot of biotech stocks lacking the attention they deserve. While this is bad news for current holders of these stocks, it is an opportunity for new ones.” With this in mind, he proceeds to highlight three “under-loved” biotech stocks…